Literature DB >> 29293143

Culture-Negative Septic Shock Compared With Culture-Positive Septic Shock: A Retrospective Cohort Study.

Shravan Kethireddy1,2, Beliz Bilgili3, Amanda Sees4, H Lester Kirchner4, Uchenna R Ofoma1, R Bruce Light5, Yazdan Mirzanejad6, Dennis Maki7, Aseem Kumar8, A Joseph Layon1, Joseph E Parrillo9, Anand Kumar5.   

Abstract

OBJECTIVES: To determine the clinical characteristics and outcomes of culture-negative septic shock in comparison with culture-positive septic shock.
DESIGN: Retrospective nested cohort study.
SETTING: ICUs of 28 academic and community hospitals in three countries between 1997 and 2010.
SUBJECTS: Patients with culture-negative septic shock and culture-positive septic shock derived from a trinational (n = 8,670) database of patients with septic shock.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: Patients with culture-negative septic shock (n = 2,651; 30.6%) and culture-positive septic shock (n = 6,019; 69.4%) were identified. Culture-negative septic shock compared with culture-positive septic shock patients experienced similar ICU survival (58.3% vs 59.5%; p = 0.276) and overall hospital survival (47.3% vs 47.1%; p = 0.976). Severity of illness was similar between culture-negative septic shock and culture-positive septic shock groups ([mean and SD Acute Physiology and Chronic Health Evaluation II, 25.7 ± 8.3 vs 25.7 ± 8.1]; p = 0.723) as were serum lactate levels (3.0 [interquartile range, 1.7-6.1] vs 3.2 mmol/L [interquartile range, 1.8-5.9 mmol/L]; p = 0.366). As delays in the administration of appropriate antimicrobial therapy after the onset of hypotension increased, patients in both groups experienced congruent increases in overall hospital mortality: culture-negative septic shock (odds ratio, 1.56; 95% CI [1.47-1.66]; p < 0.0001) and culture-positive septic shock (odds ratio, 1.65; 95% CI [1.59-1.71]; p < 0.0001).
CONCLUSIONS: Patients with culture-negative septic shock behave similarly to those with culture-positive septic shock in nearly all respects; early appropriate antimicrobial therapy appears to improve mortality. Early recognition and eradication of infection is the most obvious effective strategy to improve hospital survival.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29293143     DOI: 10.1097/CCM.0000000000002924

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  19 in total

1.  Inducible Nitric Oxide Synthase in Circulating Microvesicles: Discovery, Evolution, and Evidence as a Novel Biomarker and the Probable Causative Agent for Sepsis.

Authors:  Robert J Webber; Richard M Sweet; Douglas S Webber
Journal:  J Appl Lab Med       Date:  2019-01

2.  Clinical and microbiological outcomes, by causative pathogen, in the ASPECT-NP randomized, controlled, Phase 3 trial comparing ceftolozane/tazobactam and meropenem for treatment of hospital-acquired/ventilator-associated bacterial pneumonia.

Authors:  Ignacio Martin-Loeches; Jean-François Timsit; Marin H Kollef; Richard G Wunderink; Nobuaki Shime; Martin Nováček; Ülo Kivistik; Álvaro Réa-Neto; Christopher J Bruno; Jennifer A Huntington; Gina Lin; Erin H Jensen; Mary Motyl; Brian Yu; Davis Gates; Joan R Butterton; Elizabeth G Rhee
Journal:  J Antimicrob Chemother       Date:  2022-03-31       Impact factor: 5.758

Review 3.  Antimicrobial Treatment Duration in Sepsis and Serious Infections.

Authors:  Lindsay M Busch; Sameer S Kadri
Journal:  J Infect Dis       Date:  2020-07-21       Impact factor: 5.226

4.  Towards personalized guidelines: using machine-learning algorithms to guide antimicrobial selection.

Authors:  Ed Moran; Esther Robinson; Christopher Green; Matt Keeling; Benjamin Collyer
Journal:  J Antimicrob Chemother       Date:  2020-09-01       Impact factor: 5.790

5.  Comparison of culture-negative and culture-positive sepsis or septic shock: a systematic review and meta-analysis.

Authors:  Yuting Li; Jianxing Guo; Hongmei Yang; Hongxiang Li; Yangyang Shen; Dong Zhang
Journal:  Crit Care       Date:  2021-05-08       Impact factor: 9.097

6.  Prognosis of pathogen-proven acute respiratory distress syndrome diagnosed from a protocol that includes bronchoalveolar lavage: a retrospective observational study.

Authors:  Michihito Kyo; Koji Hosokawa; Shinichiro Ohshimo; Yoshiko Kida; Yuko Tanabe; Nobuaki Shime
Journal:  J Intensive Care       Date:  2020-07-23

7.  An overview of positive cultures and clinical outcomes in septic patients: a sub-analysis of the Prehospital Antibiotics Against Sepsis (PHANTASi) trial.

Authors:  Rishi S Nannan Panday; Eline M J Lammers; Nadia Alam; Prabath W B Nanayakkara
Journal:  Crit Care       Date:  2019-05-21       Impact factor: 9.097

8.  Risk Factors for Same Pathogen Sepsis Readmission Following Hospitalization for Septic Shock.

Authors:  June-Sung Kim; Youn-Jung Kim; Seung Mok Ryoo; Chang Hwan Sohn; Shin Ahn; Dong Woo Seo; Kyoung Soo Lim; Won Young Kim
Journal:  J Clin Med       Date:  2019-02-03       Impact factor: 4.241

9.  Multidrug-resistant organisms: A significant cause of severe sepsis in pediatric intestinal and multi-visceral transplantation.

Authors:  Alicia M Alcamo; Mira K Trivedi; Carly Dulabon; Christopher M Horvat; Geoffrey J Bond; Joseph A Carcillo; Michael Green; Marian G Michaels; Rajesh K Aneja
Journal:  Am J Transplant       Date:  2021-07-28       Impact factor: 8.086

10.  Lung penetration, bronchopulmonary pharmacokinetic/pharmacodynamic profile and safety of 3 g of ceftolozane/tazobactam administered to ventilated, critically ill patients with pneumonia.

Authors:  Luzelena Caro; David P Nicolau; Jan J De Waele; Joseph L Kuti; Kajal B Larson; Elaine Gadzicki; Brian Yu; Zhen Zeng; Adedayo Adedoyin; Elizabeth G Rhee
Journal:  J Antimicrob Chemother       Date:  2020-06-01       Impact factor: 5.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.